This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perera, M. Articles by Lumsden, M.-A. Search for Related Content PubMed PubMed Citation Articles by Perera, M. Articles by Lumsden, M.-A.

The Effects of Transdermal Estradiol in Combination with Oral Norethisterone on Lipoproteins, Coagulation, and Endothelial Markers in Postmenopausal Women with Type 2 Diabetes: A Randomized, Placebo-Controlled Study

Diabetes Center, West Glasgow Hospitals National Health Service Trust (M.P., M.S.); and Departments of Medicine and Therapeutics (J.R.P., C.H., M.S., J.M.C.C.), Pathological Biochemistry (N.S.), Medicine (J.R.P., G.D.O.L.), and Obstetrics and Gynecology (M.P., M.-A.L.), University of Glasgow, Glasgow G31 2ER, Scotland

Address all correspondence and requests for reprints to: Dr. Naveed Sattar, University Department of Pathological Biochemistry, Glasgow Royal Infirmary, University National Health Service Trust, Glasgow G31 2ER, Scotland. E-mail: nsattar{at}clinmed.gla.ac.uk

People with type 2 diabetes have a substantially increased risk of coronary heart disease (CHD). Short-term studies with unopposed oral estradiol in women with diabetes have suggested potentially beneficial effects on lipids, thrombotic factors, and insulin sensitivity. However, most (nonhysterectomized) postmenopausal women require combined estrogen-progesterone preparations. We randomized 43 women with type 2 diabetes either to continuous transdermal estradiol (80-µg patches) in combination with oral norethisterone (1 mg daily) or to identical placebos. Blood samples were taken before and after 6 months for measurement of lipoproteins, coagulation factors, and endothelial markers. Total cholesterol and triglyceride concentrations decreased by 8% and 22%, respectively, in those receiving hormone replacement therapy (P < 0.05 relative to change in placebo group after adjustment for baseline concentrations). There was a trend toward a reduction in high density lipoprotein cholesterol concentration (P = 0.06). Factor VII activity decreased by 16% (P < 0.001), and von Willebrand factor antigen decreased by 7% (P = 0.014) with active treatment. Levels of fibrinogen, tissue plasminogen activator, fibrin D dimer, very low density lipoprotein cholesterol, low density lipoprotein cholesterol, lipoprotein(a), and leptin were not significantly altered. No change in glycemic control was detected. Overall, lipid changes may be considered slightly beneficial with respect to CHD risk. The significant decrease in factor VII activity in this study is notable, because elevated factor VII activity has been associated with an increased risk of coronary thrombosis and normally increases with administration of oral estrogen-containing preparations. In addition, a reduction in von Willebrand factor antigen is consistent with an improvement in endothelial function. We suggest that the regimen used in this study may have the potential to reduce CHD risk in women with type 2 diabetes.

This article has been cited by other articles:

				J. V. Johnson, J. Lowell, G. J. Badger, J. Rosing, S. Tchaikovski, and M. Cushman Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers: A Randomized Controlled Trial Obstet. Gynecol., February 1, 2008; 111(2): 278 - 284. [Abstract] [Full Text] [PDF]

				R. H. Straub The Complex Role of Estrogens in Inflammation Endocr. Rev., August 1, 2007; 28(5): 521 - 574. [Abstract] [Full Text] [PDF]

				S. H. Golden, A. S. Dobs, D. Vaidya, M. Szklo, S. Gapstur, P. Kopp, K. Liu, and P. Ouyang Endogenous Sex Hormones and Glucose Tolerance Status in Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1289 - 1295. [Abstract] [Full Text] [PDF]

				S. Fenkci, V. Fenkci, M. Yilmazer, M. Serteser, and T. Koken Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension Hum. Reprod., April 1, 2003; 18(4): 866 - 870. [Abstract] [Full Text] [PDF]

				A. M. Kanaya, D. Herrington, E. Vittinghoff, F. Lin, D. Grady, V. Bittner, J. A. Cauley, and E. Barrett-Connor Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, January 7, 2003; 138(1): 1 - 9. [Abstract] [Full Text] [PDF]

				A. Ferrara, A. J. Karter, and J. V. Selby Hormone Replacement Therapy and Glycemic Control: Evidence from Observational Studies and Randomized Clinical Trials: Response to Dr. Aquilar-Salinas et al. Diabetes Care, January 1, 2002; 25(1): 246 - 247. [Full Text]